Clinical trials: Hepatitis C Virus
Hepatitis C, Chronic
ANNAPURNA: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Naïve or Have Previously Experienced a Null Response to Interferon-Based Treatment
This randomized, open-label, multicenter study will evaluate the safety , efficacy and tolerability of the combination treatment RO5466731, RO5190591, ritonavir and Copegus (ribavirin) with or without RO5024048 in patients with…
- Trial name
- NCT01628094
- Testing
- RO5024048, RO5190591, RO5466731
- Where
- 31 sites in United States, Australia and 3 more
- Volunteers
- 110 people
- Sponsor
- Hoffmann-La Roche
HIV Infections
Safety and Antiviral Activity of TPV in HCV and/or HBV HIV Coinfected Patients TDM Randomised Pilot Evaluation
The main purposes of this study are: demonstrate the safety and efficacy of TPV/r among HCV or hepatitis B virus (HBV) co-infected HIV+population, three-class (NRTI, NNRTI, and PI) experienced, with documented resistance to more…
- Trial name
- NCT00447902
- Testing
- tipranavir, ritonavir
- Where
- 30 sites in United States, Argentina and 5 more
- Volunteers
- 11 people
- Sponsor
- Boehringer Ingelheim
Hepatitis C
Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection
The purpose of this study is to compare the effectiveness of BMS-790052 (Daclatasvir) and Telaprevir when given in combination with Peginterferon alfa-2a and Ribavirin in genotype 1b patients
- Trial name
- COMMAND-3 (NCT01492426)
- Testing
- Daclatasvir, Telaprevir, Peginterferon alfa-2a
- Where
- 91 sites in United States, Argentina and 14 more
- Volunteers
- 605 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis, Hepatitis C, Chronic
PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis C Subjects Who Failed Response to Alpha-Interferon Plus Ribavirin (Study P02370)
The objective of this study is to determine the effectiveness of PEG-Intron 1.5 ug/kg/wk plus REBETOL (ribavirin) 800-1400 mg/day in adults with chronic hepatitis C with moderate to severe liver fibrosis or cirrhosis who failed…
- Conditions
- Hepatitis, Hepatitis C, Chronic, Fibrosis, Liver Cirrhosis
- Trial name
- NCT00039871
- Testing
- PegIntron (peginterferon alfa-2b; SCH 54031), REBETOL (ribavirin; SCH 18908)
- Volunteers
- 2,333 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
An Efficacy and Safety Study of a 8 or 12-Week Treatment Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naive and Experienced Participants With Chronic Genotype 4 Hepatitis C Virus Infection
The purpose of this study is to evaluate the efficacy of simeprevir in combination with sofosbuvir for 8 or 12 weeks versus a historical control, with respect to the percentage of participants with sustained virologic response at…
- Trial name
- NCT02278419
- Testing
- Simeprevir, Sofosbuvir
- Where
- 2 sites in Egypt
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Janssen-Cilag International NV
Hepatitis C
A Study to Examine the Effects of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus in Healthy Adults
The purpose of this study is to evaluate the effect that telaprevir has on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacokinetics means how the drug is absorbed into the bloodstream, distributed in the body and…
- Trial name
- NCT01038167
- Testing
- telaprevir, cyclosporine, tacrolimus
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
Hepatitis C, Chronic
Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM2)
The current trial is designed to prospectively explore the safety of erythropoietin use for the treatment of anemia during boceprevir plus peginterferon alfa-2b/Ribavirin (PEG2b/RBV) therapy and to assess its relationship to…
- Trial name
- NCT01023035
- Testing
- Boceprevir, Peginterferon alfa-2b (PEG2b), Ribavirin (RBV)
- Volunteers
- 687 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
A Study to Evaluate the Efficacy, Safety and Tolerability of TMC435 in Combination With PegIFN Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naïve or Treatment-Experienced, Chronic Hepatitis C Virus Genotype-4 Infected Patients
The purpose of this study to evaluate the efficacy, safety and tolerability of TMC435 in combination with Peginterferon alfa-2a (PegINF alfa-2a) and ribavirin (RBV) in both treatment-naïve and treatment experienced, chronic…
- Trial name
- RESTORE (NCT01567735)
- Testing
- TMC435
- Where
- 8 sites in Belgium, France
- Volunteers
- 107 people
- Sponsor
- Janssen R&D Ireland
Hepatitis C
Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants
Evaluate safety, tolerability, and antiviral response of ACH-0141625 compared to standard of care in hepatitis C virus (HCV)-positive participants.
- Trial name
- NCT01180790
- Testing
- ACH-0141625 (Sovaprevir), Pegylated Interferon alpha-2a, Ribavirin
- Where
- 18 sites in United States, Belgium
- Volunteers
- 122 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Hepatitis C
Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1
This study will assess the safety and efficacy of alisporivir (ALV) and boceprevir (BOC), each in combination with Peginterferon alfa-2a (PEG) and Ribavirin (RBV), in African American participants who have never received…
- Trial name
- NCT01446250
- Testing
- Alisporivir, Boceprevir, Peginterferon alfa-2a
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Debiopharm International SA
Hepatitis C
Evaluation of Peginterferon Alfa-2b Monotherapy and Combination With Ribavirin in Participants With Acute Hepatitis C (P03552/MK-4031-137)
The objective of this study is to evaluate the efficacy of three regimens of pegylated interferon-alfa 2b (PEG-IFN) either as monotherapy or in combination with ribavirin in participants with acute hepatitis C.
- Trial name
- NCT00686517
- Testing
- Pegylated interferon alfa-2b, Ribavirin
- Volunteers
- 130 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Chronic
A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS With or Without COPEGUS in Patients With Chronic Hepatitis C (CHC) Genotype 1 Infection.
This 4 arm study will compare the safety and tolerability of HCV polymerase inhibitor pro-drug in combination with PEGASYS +/- COPEGUS with the standard of care therapy of PEGASYS + COPEGUS, in treatment-naive patients with CHC…
- Trial name
- NCT00377182
- Testing
- Copegus, PEGASYS, RO5024048 1500mg
- Where
- 18 sites in United States, Puerto Rico
- Volunteers
- 107 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic
Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and Ritonavir When Administered in Combination in Healthy Participants (MK-1894-007)
The purpose of this study is to evaluate the potential for a PK drug-drug interaction when IDX719, simeprevir, TMC647055 and low-dose ritonavir (RTV) are administered in combination. Safety and tolerability will also be assessed.
- Trial name
- NCT01907724
- Testing
- IDX719, Simeprevir, TMC647055
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C Virus
TMC435-TiDP16-C114 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and the Antiretroviral Agents TMC278 and Tenofovir
The purpose of this study is to investigate the effect of steady-state concentrations of TMC435 on the steady-state pharmacokinetics of TMC278 or Tenofovir , and vice versa.
- Trial name
- NCT01205139
- Testing
- TMC435, TDF, TMC435 + TDF
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Hepatitis C Virus Infection
Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection
The primary objectives of the study are to evaluate the safety, tolerability, and efficacy of voxilaprevir (VOX) plus sofosbuvir/velpatasvir (SOF/VEL) fixed dose combination (FDC) in adults with chronic non genotype 1 hepatitis C…
- Trial name
- NCT02378961
- Testing
- VOX, SOF/VEL
- Where
- 34 sites in United States, New Zealand and 1 more
- Volunteers
- 128 people
- Sponsor
- Gilead Sciences
Hepatitis C
Effectiveness Of Daclatasvir-Based Regimens In Patients With Chronic Hepatitis C Infection In Europe: Experience From Named Patient Program And From Early Post-Marketing Authorization Period
Using European data from patients included in the Named Patient Program (NPP) and from the early post-marketing authorization period, the present study aims to describe patient characteristics and to describe the effectiveness of…
- Trial name
- NCT02531269
- Where
- Switzerland
- Volunteers
- 249 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C
Evaluation of MK-1075 in Participants With Hepatitis C Virus (HCV) Infection (MK-1075-002)
The purpose of this study is to evaluate the safety and pharmacokinetics of MK-1075, and to determine the ability of MK-1075 to reduce HCV viral load, following administration of a single dose in HCV-infected participants.
- Trial name
- NCT02392494
- Testing
- MK-1075
- Volunteers
- 9 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C
A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C
The purpose of the study is to determine the safety, pharmacokinetics and efficacy of orally administered VX-135 with ribavirin in treatment naive subjects with chronic hepatitis C infection.
- Trial name
- NCT01790100
- Testing
- VX-135, Ribavirin
- Where
- Moldova
- Volunteers
- 20 people
- Sponsor
- Alios Biopharma Inc.
Hepatitis C
A Study to Investigate the Potential Pharmacokinetic Interaction Between TMC435 and Methadone
The purpose of this study is to evaluate the effect of steady-state (constant concentration of medication in the blood) TMC435 (150 mg, once a day) on the steady state pharmacokinetics (what the body does to the medication) of R…
- Trial name
- NCT00915564
- Testing
- TMC435, Methadone
- Where
- Canada
- Volunteers
- 13 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Hepatitis C Virus
A Study to Examine Patient Characteristics, Health Care Management and Health Outcomes of Hepatitis C Virus (HCV) Patients Treated With Simeprevir
The purpose of this study is to evaluate the effectiveness of a simeprevir-containing hepatitis C virus (HCV) treatment regimen as measured by sustained virologic response (SVR).
- Trial name
- NCT02103699
- Testing
- No intervention
- Where
- 32 sites in United States
- Volunteers
- 315 people
- Sponsor
- Janssen Scientific Affairs, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.